OptiNose (OPTN) Stock Price, News & Analysis

Company Overview

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Key Stats

• Today's Range: $9.60 to $9.60
• 50-Day Range: $9.38 to $9.71
• 52-Week Range: $9.18 to $9.75
• Volume: N/A
• Average Volume: 71,189 shs
• Market Capitalization: $97.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Hold

OPTN Stock Analysis - Frequently Asked Questions

How were OptiNose's earnings last quarter?

OptiNose, Inc. (NASDAQ:OPTN) issued its earnings results on Tuesday, May, 13th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.74) by $0.27. The business earned $18.51 million during the quarter, compared to analysts' expectations of $17.70 million.

When did OptiNose's stock split?

OptiNose's stock reverse split on Tuesday, December 31st 2024.The 1-15 reverse split was announced on Thursday, December 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did OptiNose IPO?

OptiNose (OPTN) raised $120 million in an initial public offering on Friday, October 13th 2017. The company issued 7,500,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO.

What other stocks do shareholders of OptiNose own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OptiNose investors own include NVIDIA (NVDA), GE Aerospace (GE), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET) and Adobe (ADBE).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OPTN
• CIK: 1494650
• Web: www.optinose.com
• Phone: (267) 364-3500
• Fax: N/A
• Employees: 190
• Year Founded: 2000

Price Target and Rating

• Average Price Target for OptiNose: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: -6.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.48 million
• Net Margins: -41.16%
• Pretax Margin: -41.16%
• Return on Equity: N/A
• Return on Assets: -27.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.79
• Quick Ratio: 0.72

Sales & Book Value

• Annual Sales: $81.86 million
• Price / Sales: 1.19
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($11.56) per share
• Price / Book: -0.83

Miscellaneous

• Outstanding Shares: 10,127,000
• Free Float: 9,829,000
• Market Cap: $97.22 million
• Optionable: Not Optionable
• Beta: -0.88